A Study of Pumitamig Alone or in Combination with Ipilimumab or Cabozantinib in People With Renal Cell Carcinoma

Full Title

ROSETTA RCC-208: A Phase 1/2 Open-label, Multi-center, Randomized Study of Pumitamig Alone or in Combination with Ipilimumab or Cabozantinib in Participants with Advanced Renal Cell Carcinoma (RCC)

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Sahil Doshi’s office at 646-422-4341.

Protocol
26-186
Phase
Phase I/II (phases 1 and 2 combined)
Investigator
Sahil D. Doshi
Co-Investigators
Robert J. Motzer
Diseases
Genitourinary Cancer › Kidney Cancer
Locations
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau
ClinicalTrials.gov ID
NCT07293351
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description